Journal of Microbiology and Biotechnology

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지

7-Oxostaurosporine Selectively Inhibits the Mycelial Form of Candida albicans

  • Hwang, Eui-Il (Bio Research Group, KT&G Central Research Institute) ;
  • Yun, Bong-Sik (Laboratory of Cellular Function Modulator, Korea Research Institute of Bioscience and Biotechnology) ;
  • Lee, Sang-Han (Laboratory of Cellular Function Modulator, Korea Research Institute of Bioscience and Biotechnology) ;
  • Kim, Soo-Kie (Department of Microbiology, Wonju College of Medicine, IFBB, Yonsei University) ;
  • Lim, Se-Jin (College of Pharmacy, Dongduk Women's University) ;
  • Kim, Sung-Uk (Laboratory of Cellular Function Modulator, Korea Research Institute of Bioscience and Biotechnology)
  • Published : 2004.10.01
Download PDF
⟨ Previous Next ⟩

Abstract

In the course of screening for specific inhibitors against the mycelial form of Candida albicans from natural resources, we have isolated and identified A6792-1 from Streptomyces sp. A6792 by using several chromatographies. By spectral analyses, this compound was determined as 7-oxostaurosporine, having a structure of staurosporine aglycon noiety. 7-Oxostaurosporine exhibited a selective growth inhibitory activity against the mycelial form of Candida spp. up to $100\mu\textrm{g}/disc$ in bioassay. It also exhibited a specific antifungal activity against the mycelial form of Candida spp. including C. krusei, C. albicans, C. tropicalis, and C. lusitaniae with MICs ranging from 3.1 to $25\mu\textrm{g}/ml$ 7-Oxostaurosporine demonstrated no in vivo toxicity in SPF ICR mice. Therefore, this compound may have a considerable potential as an antifungal agent based on the preferential inhibition against growth of the mycelial form of Candida spp., dimorphic fungi.

Keywords

References

  1. Calderone, R. A. and W. A. Fonzi. 2001. Virulence factors of Candida albicans. Trends Microbial. 9(7): 327- 335.
  2. Cassone, A. 1986. Cell wall of pathogenic yeasts and implications for antimycotic therapy. Drugs Exptl. Clin. Res. 12: 635- 643.
  3. Gullo, V., L. Gunnarsson, V. Hegde, A. Horan, D. Loebenberg, J. Marquez, M. Petel, M. Pular, and J. Schwartz. 1991. A novel antifungal from an actinomadurae with preferential activity against the mycelial phase of Candida albicans. J. Ind. Microbial. 8: 65- 68.
  4. Koshino, H., H. Osada, and K. Isono. 1992. A new inhibitor of protein kinase C, RK-1409 (7-oxostaurosporine). II. Fermentation, isolation, physico-chemical properties and structure. J. Antibiotics 45(2): 195- 198.
  5. Lo, H. J., J. R. Kohler, B. DiDomenico, D. Loebenberg, A. Cacciapuoti, and G. R. Fink. 1997. Nonfilamentous C. albicans mutants are avirulent. Cell 90: 939- 949.
  6. Lorian, V. 1986. Antibiotics in Laboratory Medicine. 2nd Ed. Williams & Wilkins, Baltimore.
  7. Milewaki, S., H. Chmara, and E. Borowaki. 1983. Growth inhibitory effect of antibiotic tetaine on yeast and mycelial forms of Candida albicans. Arch. Microbial. 135: 130- 136.
  8. Odds, F. C. 1988. Candida and Candidosis. 2nd Ed. Balliere Tindall, London.
  9. Omura, S., Y. Sasaki, Y. Iwai, and H. Takeshima. 1995. Staurosporine, a potentially importantgiftfrom a microorganism. J. Antibiotics 48(7): 535- 548.
  10. Osada, H., H. Koshino, T. Kudo, R. Onose, and K. Isono. 1992. A new inhibitor of protein kinase C, RK-1409 (7oxostaurosporine). I. Taxonomy and biological activity. J. Antibiotics 45(2): 189- 194.